

The JAVELIN Gastric 300 data will be further examined in an effort to better understand the results and will also be submitted

for presentation at an upcoming medical congress.

The outcome of JAVELIN Gastric 300 does not have any impact on current avelumab approvals.

JAVELIN Gastric 300 is a Phase III, clinical trial investigating avelumab versus physician's choice of protocol-specified chemotherapy plus best supportive care in patients with unresectable adenocarcinoma whose disease has progressed following two prior therapeutic regimens.

The trial enrolled 371 patients from 147 sites in Asia, Australia, Europe, North America and South America. The primary endpoint was OS.

The avelumab gastric clinical development program also includes JAVELIN Gastric 100, a multicenter, randomized, open-label Phase III study.

It evaluates avelumab as first-line maintenance therapy following induction chemotherapy in unresectable gastric cancer. The trial will continue as planned.

Avelumab is under clinical investigation for treatment of gastric/GEJ cancer and has not been demonstrated to be safe and effective for this indication.

There is no guarantee that avelumab will be approved for gastric/GEJ cancer by any health authority worldwide.